Manske Wealth Management’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.18M Buy
24,546
+7,373
+43% +$317K 0.29% 62
2026
Q1
$631K Buy
17,173
+12,293
+252% +$582K 0.18% 99
2025
Q4
$248K Buy
+4,880
New +$250K 0.07% 184

Other funds holding NVO

Manske Wealth Management's NVO Position: Q2 2026 in Review

Manske Wealth Management increased its Novo Nordisk (NVO) stake by 43% in Q2 2026, buying an estimated $317K and bringing the position to 24,546 shares worth $1.18M. The position accounts for 0.29% of the portfolio, ranked #62.

Manske Wealth Management first reported a position in NVO in Q4 2025 and has held it in 3 quarters since. 1,356 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Manske Wealth Management held 24,546 shares of Novo Nordisk worth $1.18M as of Q2 2026.
  • Manske Wealth Management bought 7,373 Novo Nordisk shares in Q2 2026, an estimated $317K.
  • Novo Nordisk made up 0.29% of Manske Wealth Management's portfolio in Q2 2026, its #62 holding.
  • Manske Wealth Management first reported a position in Novo Nordisk in Q4 2025 and has held it in 3 quarters since.
  • 1,356 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Manske Wealth Management's 13F filing for Q2 2026, filed 3 Aug 2026.